Last reviewed · How we verify
angiotensin blockade
Angiotensin blockade inhibits the renin-angiotensin-aldosterone system (RAAS) to reduce vasoconstriction and lower blood pressure.
Angiotensin blockade inhibits the renin-angiotensin-aldosterone system (RAAS) to reduce vasoconstriction and lower blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | angiotensin blockade |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Angiotensin receptor blocker (ARB) or ACE inhibitor |
| Target | Angiotensin II type 1 receptor (AT1R) or Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Angiotensin II is a potent vasoconstrictor that plays a central role in blood pressure regulation and cardiovascular remodeling. By blocking angiotensin II receptors (ARBs) or inhibiting angiotensin-converting enzyme (ACE inhibitors), this mechanism reduces peripheral vascular resistance, decreases aldosterone secretion, and promotes sodium and water excretion, leading to reduced blood pressure and improved cardiac function.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Hyperkalemia
- Hypotension
- Dizziness
- Cough (ACE inhibitors)
- Renal impairment
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Transformative Research in Diabetic Nephropathy 2.0
- Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD (PHASE2)
- Losartan to Improve Outcomes After Multi-ligament Knee Injury (PHASE2)
- Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. (NA)
- Treatment of IgA Nephropathy According to Renal Lesions (PHASE3)
- : Vascular Function in Health and Disease (PHASE1)
- Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- angiotensin blockade CI brief — competitive landscape report
- angiotensin blockade updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI